| Title |
Projecting Expenditure on Medicines in the UK NHS
|
|---|---|
| Published in |
PharmacoEconomics, September 2013
|
| DOI | 10.1007/s40273-013-0082-1 |
| Pubmed ID | |
| Authors |
Phill O’Neill, Jorge Mestre-Ferrandiz, Ruth Puig-Peiro, Jon Sussex |
| Abstract |
Expenditure on medicines is a readily identifiable element of health service costs. It is the focus of much attention by payers, not least in the UK even though the cost of medicines represents less than 10 % of total UK National Health Service (NHS) expenditure. Projecting future medicines spending enables the likely cost pressure to be allowed for in planning the scale and allocation of NHS resources. Simple extrapolations of past trends in expenditure fail to account for changes in the rate and mix of new medicines becoming available and in the scope for windfall savings when some medicines lose their patent protection. The objective of this study is to develop and test an improved method to project NHS pharmaceutical expenditure in the UK for the period 2012-2015. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 25% |
| New Zealand | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 3% |
| Spain | 1 | <1% |
| Australia | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 141 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 19 | 13% |
| Researcher | 12 | 8% |
| Professor | 4 | 3% |
| Other | 3 | 2% |
| Professor > Associate Professor | 3 | 2% |
| Other | 10 | 7% |
| Unknown | 97 | 66% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 10% |
| Economics, Econometrics and Finance | 11 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Business, Management and Accounting | 6 | 4% |
| Nursing and Health Professions | 2 | 1% |
| Other | 6 | 4% |
| Unknown | 99 | 67% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2022.
All research outputs
#5,465,413
of 22,782,096 outputs
Outputs from PharmacoEconomics
#600
of 1,816 outputs
Outputs of similar age
#46,192
of 197,653 outputs
Outputs of similar age from PharmacoEconomics
#5
of 13 outputs
Altmetric has tracked 22,782,096 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,816 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,653 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.